NCT06570824 rTMS as an Intervention for Levodopa-induced Dyskinesia
| NCT ID | NCT06570824 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Danish Research Centre for Magnetic Resonance |
| Condition | Dyskinesia, Drug-Induced |
| Study Type | INTERVENTIONAL |
| Enrollment | 68 participants |
| Start Date | 2024-08-22 |
| Primary Completion | 2027-05-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 68 participants in total. It began in 2024-08-22 with a primary completion date of 2027-05-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The proposed study investigates the use of repetitive transcranial magnetic stimulation (rTMS) as a treatment for levodopa-induced dyskinesia (LID) in Parkinson's Disease (PD). Specifically, the study aims to determine whether patterned stimulation of the pre-supplementary motor area (pre-SMA) can delay the onset of LID after levodopa intake and reduce LID severity in PD patients. This study will provide critical insights into potential targets for rTMS treatment, optimal rTMS parameters, and the mechanisms underlying LID in Parkinson's disease.
Eligibility Criteria
Inclusion Criteria: * Clinically established or probable PD * Clinical Diagnostic Criteria for Parkinson's Disease * Peak-of-dose levodopa-induced dyskinesia. * Stable antiparkinsonian medicine for at least four weeks. * Signed informed consent. Exclusion Criteria: * Psychiatric disorders. * Usage of antipsychotic medication, Donepezil, and GABAergic medications (such as pregabalin and gabapentin). * Regular usage of benzodiazepines and opioids (more than once per week). * History of neurological disease other than Parkinson's disease. * History of epilepsy/conditions associated with increased risk to seizure-induction through TMS. * Close relatives suffering from epilepsy/conditions associated with increased risk to seizure-induction through TMS. * Contraindications for MRI scan * Female participants of childbearing age must not be pregnant and that they must use contraception during the trial. * Refuse to be informed about new health related information and accidental health related findings that might appear through participation in the study.
Contact & Investigator
Hartwig R. Siebner, Prof.
PRINCIPAL INVESTIGATOR
Head of Research, Prof, DMSc
Frequently Asked Questions
Who can join the NCT06570824 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Dyskinesia, Drug-Induced. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06570824 currently recruiting?
Yes, NCT06570824 is actively recruiting participants. Contact the research team at laura.sakalauskaite.01@regionh.dk for enrollment information.
Where is the NCT06570824 trial being conducted?
This trial is being conducted at Hvidovre, Denmark.
Who is sponsoring the NCT06570824 clinical trial?
NCT06570824 is sponsored by Danish Research Centre for Magnetic Resonance. The principal investigator is Hartwig R. Siebner, Prof. at Head of Research, Prof, DMSc. The trial plans to enroll 68 participants.